Publications by authors named "R A Kesterson"

RANKL and its receptor RANK play a vital role in osteoclastogenesis. RANK primarily recruits TRAFs to promote osteoclastogenesis but also contains an TRAF-independent motif (IVVY), which mediates osteoclast lineage commitment in vitro. Here, we have developed knockin mice in which inactivating mutations are introduced in the IVVY motif (IVVY to IVAF).

View Article and Find Full Text PDF

Neurofibromatosis Type 1 (NF1) is caused by loss of function variants in the NF1 gene. Most patients with NF1 develop skin lesions called cutaneous neurofibromas (cNFs). Currently the only approved therapeutic for NF1 is selumetinib, a mitogen -activated protein kinase (MEK) inhibitor.

View Article and Find Full Text PDF

Background: With the recognition that noncancerous cells function as critical regulators of brain tumor growth, we recently demonstrated that neurons drive low-grade glioma initiation and progression. Using mouse models of neurofibromatosis type 1 (NF1)-associated optic pathway glioma (OPG), we showed that Nf1 mutation induces neuronal hyperexcitability and midkine expression, which activates an immune axis to support tumor growth, such that high-dose lamotrigine treatment reduces Nf1-OPG proliferation. Herein, we execute a series of complementary experiments to address several key knowledge gaps relevant to future clinical translation.

View Article and Find Full Text PDF
Article Synopsis
  • * Gene-targeted therapies show potential to address these limitations, but challenges in preclinical and clinical testing, as well as delivery methods, need to be resolved first.
  • * Developing better preclinical models, validated assays to measure specific protein activities, and educating patients and clinicians about the risks and benefits of these therapies is crucial for future advancements.
View Article and Find Full Text PDF